Columbus Circle Investors’s Ocular Therapeutix OCUL Stock Holding History

Columbus Circle Investors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,072,395	Closed	-$6.63M	–	244
2017 Q3	$6.63M	Buy	1,072,395 +494,867	+86%	+$3.19M	0.11%	153
2017 Q2	$5.35M	Sell	577,528 -510,077	-47%	-$4.94M	0.09%	157
2017 Q1	$10.1M	Buy	1,087,605 +617,515	+131%	+$5.14M	0.14%	147
2016 Q4	$3.94M	Sell	470,090 -21,114	-4%	-$164K	0.05%	202
2016 Q3	$3.38M	Buy	491,204 +212,419	+76%	+$1.29M	0.04%	222
2016 Q2	$1.38M	Buy	278,785 +90,283	+48%	+$895K	0.01%	219
2016 Q1	$1.82M	Buy	188,502 +85,643	+83%	+$649K	0.02%	223
2015 Q4	$964K	Buy	102,859 +36,747	+56%	+$397K	0.01%	255
2015 Q3	$930K	Buy	+66,112	New	+$1.33M	0.01%	250

Other funds holding OCUL

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Columbus Circle Investors's OCUL Position: Q4 2017 in Review

Columbus Circle Investors sold out of Ocular Therapeutix (OCUL) in Q4 2017, closing a stake of 1,072,395 shares — an estimated $6.63M sold.

Columbus Circle Investors first reported a position in OCUL in Q3 2015 and held it in 9 quarters. The position peaked at $10.1M in Q1 2017. 69 funds tracked by Wall St. Rank hold OCUL as of Q4 2017.

Columbus Circle Investors reported no remaining Ocular Therapeutix position as of Q4 2017 after selling out during the quarter.
Columbus Circle Investors sold 1,072,395 Ocular Therapeutix shares in Q4 2017, an estimated $6.63M.
Columbus Circle Investors first reported a position in Ocular Therapeutix in Q3 2015 and held it in 9 quarters.
Columbus Circle Investors's Ocular Therapeutix position peaked at $10.1M in Q1 2017.
69 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.